title: Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
abstract: Although multiple cellular mechanisms have been proposed to explain endocrine resistance in breast cancer, the genomics events promoting the dysregulation of gene expression pattern are not clearly understood. Because chromatin plays a dynamic role in the estrogen receptor α (ERα) transcriptional program, we herein review signaling pathways implicated in endocrine resistance and try to merge them with recent epigenetic studies.
authors: Département de Biologie, Université de Sherbrooke, Sherbrooke, Québec, Canada.
authors: Stéphanie
authors: S
authors: Bianco
authors: Nicolas
authors: N
authors: Gévry
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D002843:Chromatin / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D044127:Epigenesis, Genetic; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use; D014158:Transcription, Genetic
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002843:Chromatin; D011960:Receptors, Estrogen; D013629:Tamoxifen